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EDITORIAL

PHASE III CLINICAL TRIALS: NO ETHICS NO PARADIGM
ENSAYOS CLINICOS FASE III: SIN ÉTICA NO HAY PARADIGMA
Jhony A. De La Cruz-Vargas1,a,b,c

The phase III clinical trial is the paradigm of experimental health research and is the boundary between
standard medicine and research medicine, so much so that two or more positive clinical trials support
evidence-based medicine in routine clinical practice. The therapeutic, diagnostic and preventive advances
of modern medicine rest to a large extent on the proper, ethical development and with the necessary
scientific rigor established at the international and national levels.

EDITORIAL

In order for a new treatment to be available for daily use in patients, a model was proposed for more than
four decades that consists of conducting sequential research studies, called clinical phases I, II, III and IV,
which are initiated once the beneficial effects of the drug have been proven in cell and animal models
(preclinical phase).
For the correct development of clinical trials it is necessary the responsible participation of the following
characters: 1) The national regulatory body 2) The research center (site) and the Research Team 3) CRO
and its monitors 4) Patients 5) Research Ethics Committee or IRB: Institutional Review Board 6) External
Review Committee 7) Sponsor
All of them are responsible for solidarity and unavoidable and they work to assure society and the country
the relevance of the clinical trial for the study population, the safety of the processes and the quality of
the data, the integrity of the participants, the truthfulness and strict adherence to the study protocol and
finally the scientific report and publication of the results, to only then be useful input for health decisionmaking.
In the United States, the regulatory body is the FDA: Food and Drug Administration. The other responsible
regulatory bodies are COFEPRIS in Mexico, ALMAT in Argentina and in Peru, the INS (National Institute
of Health) through the General Office of Research and Technology Transfer (OGITT) of the INS and the
REPEC: Peruvian Registry of Clinical Trials. (https://web.ins.gob.pe/es/investigacion-en-salud/acerca-dela-ogitt), offices that are in charge of the Peruvian Ministry of Health.
With regard to the research centers and the research team, it is clear that they must correspond to
institutions with characteristics and competence in research, that the research team must, in addition
to have the academic profile, possess the scientific and human aptitude, and the ethical quality to
propose and develop it, the latter being the most important. In the world, clinical research ceased to
be an exclusivity of large centers of high complexity, where patient selection biases, the availability of
advanced technology and human resources does not translate into the actual practice of most health
centers in the world, and even more so in our country. Therefore, research with pragmatic clinical trials,
closer to the social, economic and political reality of the population, even in community trials, provide
high quality evidence. From a public health perspective, working in primary health care and prevention
protocols is a necessity and not just managing or prioritizing clinical trials of interest or funded by the
pharmaceutical industry.
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EDITORIAL

The goal of a clinical trial is to test a hypothesis of
an intervention to compare it with standard gold or
the best available clinical support, which helps in the
health and quality of life of people, and not only in
economic developments of interest to a sector.
It is for the research institutions to submit and
approve in their respective local research ethics
committees the pertinence, suitability, balance of
potential benefits and risks for the participants,
and the conditions for the development of these
protocols, because it is these committees that know
the environment and the reality of the institutions.
Centralizing and monopolizing with a single
National Committee for Clinical Trials in a country of
33 million inhabitants does not seem logical, is not
equitable and does not help to promote research.
The regulatory body is responsible for promoting
and validating institutional or local ethics and
research committees, providing them with facilities
and developing continuous training programs.
CROs: Contract Research Organizations are
companies that provide support to pharmacists and
are contracted by the sponsor to perform one or
more of the sponsor’s duties and functions related
to the trial. They perform various functions before,
during and at the end of the clinical trial and their
monitoring role is highlighted with visits, records
and reports of the normal or not development of the
clinical trial.
The patients who participate in a clinical trial are
the center and reason to be a phase III study. They
deserve all the attention, their integrity must be
safeguarded, their rights respected, they must
be given all the information, and when invited to
participate they must receive and sign an informed
consent. Their participation should be voluntary,
free, informed and they should know that you they
leave the protocol at any time. They should also know
that in a phase III clinical trial, there are generally two
groups, the Intervention Group A, which will receive
the active ingredient, and the Control Group B, which
will not receive the product under investigation.
This assignment of each patient should be done in
a randomized way, which does not depend on the
patient or the researcher, to avoid study bias.
The sponsor is directly responsible for the clinical trial.
The responsibilities of the sponsor are multiple, some
of them are: apply for approval by the local Ethics
Committee, comply with national and international
requirements, emphasize the benefits of local
needs. It is essential that officials and public servants
associated with the processes of submission and
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approval of clinical trials in our country can clearly
differentiate commercial sponsors from academic
sponsors. In Peru we should encourage more
universities to participate as academic sponsors,
with the aim of truly promoting research of interest
to our country and not just approving "international
canned projects" presented by transnational, that
do not always respond to the priority needs of our
country.
Clinical trials have multiple safety padlocks, one of
them is to have “Good Clinical Practices” that every
researcher and team member must know and put
into practice, in order to avoid being a judge and
party, they must have a "External Academic Review
Committee" to the institution and the research team
that carries out the clinical trial, with people who
clearly do not present conflicts of interest.
A rigorous follow-up is necessary for a valid and
quality research. Exclusions, withdrawals and losses
generate biases and deviations from the protocol
(alteration or modification to the previously
approved protocol). A major deviation or violation of
the protocol is considered to be one that impacts the
subject’s safety, or alters the risk/benefit balance, or
compromises the integrity of the study data and/or
affects the subject’s willingness to participate in the
study. Errors in relation to the criteria of inclusion and
exclusion, error in the delivery or dosage of the drug
is considered a flagrant violation of the protocol.
The international scientific community looks with
distrust at data from studies that do not strictly meet
these criteria.
Clinical research is crucial for the advancement of
medical knowledge and patient care. In particular,
clinical trials are the cornerstone in the development
of new treatments.
Ethics mark the course of research in health, without
ethics there is no paradigm or research that benefits
people and humanity. Anywhere in the world where
ethics is taught, what happened in Peru during
the pandemic and vaccines will be mentioned as
an example of what should not be done in clinical
research. It is one thing to know about ethics and the
theory of clinical trials and quite another to put it into
practice and comply with the principles that govern
clinical trials and to transmit with the example what
is presumed in the classrooms.
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